Pharmokinetics

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biologics / Biotechnology #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology #Lead discovery #Lead optimisation #Oncology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Toxicology

Long Live Peptides – Evolution of peptide half-life extension technologies and emerging hybrid approaches

Long Live Peptides - Evolution of peptide half-life extension technologies and emerging hybrid approaches By Dr Ronald V. Swanson Among therapeutic modalities, peptides occupy a middle ground between traditional ‘small molecule’ drugs and the larger injectable biologics, not fitting comfortably into either category. Peptides, particularly those based on endogenous human… Read More

#Archive

#ADME / Tox #Analysis #Automation / robotics #Business #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmokinetics #RNA #System biology

Rules For Drug Discovery: Can simple property criteria help you to find a drug?

Rules For Drug Discovery: Can simple property criteria help you to find a drug? By Dr Matthew Segall The years since the publication of Lipinski’s Rule of Five (Ro5) (1) in 1997 have seen the growth of a minor industry, dedicated to generating new ‘rules’ for drug discovery. Fuelled by… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Oncology #Patent Law #Pharmokinetics #Regulatory #RNA #Screening #Toxicology #Translational #Translational chemistry

Highlights from GlobalData’s CRO Benchmark Report

Highlights from GlobalData’s CRO Benchmark Report By Adam M. Dion The biopharmaceutical industry is currently facing significant headwinds. The blockbuster era is over, development costs are skyrocketing, uncertainty exists around regulatory and reimbursement, patent cliffs, generic erosion and a sluggish global economy all have industry executives losing sleep at night. Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Oncology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Translational #Translational chemistry

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes Dr John Comley Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activity is demonstrated by the large… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Molecular medicine #PCR #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology

Unrevealing Biological Secrets By Single Cell Expression Profiling

Unrevealing Biological Secrets By Single Cell Expression Profiling By Dr Mikael Kubista and Dr Anders Ståhlberg During the last 30 years exceedingly sensitive and accurate technologies have been developed to measure and quantify amounts of nucleic acids and proteins. With techniques such as quantitative real-time PCR (qPCR) and nextgeneration sequencing… Read More

#Archive

#Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Microfluidics #Oncology #Pathology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Cell Migration: Probing Cell Movement With Smarter Tools

Cell Migration: Probing Cell Movement With Smarter Tools By Dr John Comley Cell migration comprises the movement of cells from one location to another in response to events, biological signals or environmental cues. Cell migration plays a critical role in numerous normal biological processes and also in many diseases. Most… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Target validation

Carbon-14 Labelled API Manufacturing

Carbon-14 Labelled API Manufacturing By Dr Sean L. Kitson and Dr David Speed Carbon-14 labelled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. The short supply… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Oncology #Pathology #Pharmacology #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry By Dr Yi Gu and William Shi As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfectly positioned to benefit from close proximity to key opinion… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Patent Law #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Innovate While Derisking Drug Development: Yes We Can!

Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in the genomics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Clinical specialities #Clinical trials #Drug development #Enabling technologies #High Content Screening #Imaging #Mass spectrometry / NMR #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Translational #Translational chemistry

In Vivo Imaging In Drug Development: Gamma Scintigraphy

In Vivo Imaging In Drug Development: Gamma Scintigraphy By Dr Alyson Connor Gamma scintigraphy is a non-invasive technique with applications in the development of drug products and the assessment of pharmacodynamic effects in humans. It enables the assessment of critical performance parameters that in vitro techniques attempt, but often fail,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation

The Apocalyptic Horsemen of Drug Discovery and Development

The Apocalyptic Horsemen of Drug Discovery and Development By Dr Gary J. Keil The pharmaceutical industry should consider an evolutionary disease management approach based on homeostasis, irreversibility, biological alinearity, pseudo-N-of-1 health and disease states and narrative medicine best practices in order to help secure a successful drug development future. The… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Therapeutics

SMAC Mimetics: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells

SMAC Mimetics: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells By Dr Mark A. McKinlay SMAC mimetics are a new class of targeted drugs being developed for the treatment of solid tumours and hematologic cancers. SMAC mimetics specifically induce apoptotic… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #Medicinal chemistry #Microfluidics #PCR #Pharmokinetics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

The Need for High Throughput Kinetics Early in the Drug Discovery Process

Dr Wilma Keighley Generally kinetics are only investigated late in a programme by which time many compounds, slightly less potent but with a much better kinetic profile, have already been discarded. This paper argues that having kinetic information at the early stages of drug discovery can bring numerous benefits to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #Imaging #Lead discovery #Lead optimisation #Oncology #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

In Vivo Preclinical Imaging – An Essential Tool in Translational Research

In Vivo Preclinical Imaging - An Essential Tool in Translational Research By Dr John Comley In vivo imaging of small animals (mainly mice) is increasingly being deployed across the drug development process, particularly in the oncology/cancer therapeutic area. One of the main applications is monitoring the treatment response for early… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #PCR #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology

The Benefits Of Drug Repositioning

The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will… Read More

#Archive

#Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Lead discovery #Oncology #Pharmokinetics #Regulatory #RNA

Balancing A Biologics Pipeline Portfolio

Balancing A Biologics Pipeline Portfolio By Dr Herren Wu Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential to offer patients significant benefits as well… Read More

#Archive